KRAS and colorectal carcinoma: Cetuximab in pretreated KRAS wild‐type CRC patients achieved the highest incremental clinical benefit (ESMO MCBS 5, ASCO VF 71.8) by achieving a relatively large OS (4.7 months, HR 0.55) and significant QOL benefit (see Table 2, which displays individual clinical benefit scores and drug prices).